Search

Your search keyword '"Casali, P. G."' showing total 411 results

Search Constraints

Start Over You searched for: Author "Casali, P. G." Remove constraint Author: "Casali, P. G."
411 results on '"Casali, P. G."'

Search Results

1. Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses

4. Shortcuts in Cosmological Branes

5. Brane World Cosmological Perturbations

11. Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis

12. Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database

13. Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended Resection

14. Mode of action of trabectedin in myxoid liposarcomas

15. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper

16. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial

17. Erratum to: Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group

19. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†

22. Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience

33. Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes: ID 011

34. Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics: ID 010

36. The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO)

Catalog

Books, media, physical & digital resources